Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Total Current Liabilities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Total Current Liabilities data on record, last reported at $242.1 million in Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 149.58% to $242.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $242.1 million, a 149.58% increase, with the full-year FY2025 number at $205.8 million, up 46.78% from a year prior.
  • Total Current Liabilities reached $242.1 million in Q1 2026 per PCVX's latest filing, up from $205.8 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for PCVX hit a ceiling of $242.1 million in Q1 2026 and a floor of $27.2 million in Q1 2022.
  • A 5-year average of $106.7 million and a median of $87.1 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 50.47% in 2022, then surged 258.64% in 2023.
  • Tracing PCVX's Total Current Liabilities over 5 years: stood at $40.5 million in 2022, then soared by 258.64% to $145.3 million in 2023, then dropped by 3.55% to $140.2 million in 2024, then soared by 46.78% to $205.8 million in 2025, then increased by 17.66% to $242.1 million in 2026.
  • Business Quant data shows Total Current Liabilities for PCVX at $242.1 million in Q1 2026, $205.8 million in Q4 2025, and $200.0 million in Q3 2025.